To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

This study is examining a new type of immune cell therapy using CAR-T cells that are engineered to target a protein called CD7 found on certain cancers. It is being tested in people with relapsed or refractory peripheral T-cell lymphoma (a type of blood cancer that has not responded to or returned after prior treatments). **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with peripheral T-cell lymphoma confirmed by biopsy - Your lymphoma has relapsed or did not respond to at least one prior treatment - Your tumor tests positive for the CD7 protein - Your heart function and general health status are adequate **You may NOT be eligible if...** - You have primary cutaneous T-cell lymphoma (e.g., mycosis fungoides) or T-lymphoblastic leukemia/lymphoma - You have active cancer in the brain or spinal fluid - You have serious heart conditions including recent heart attack or significant heart rhythm problems - You have active uncontrolled infections, active hepatitis B/C, HIV, or active syphilis - You have autoimmune diseases requiring ongoing treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.